Drugs Acting on the Central Nervous System: A Review

Swapnali kondke[1], gayatri muley[2], Mr.Hatkar Avinash D[3], Mr.S.V. Phoke[4], Mr.Dr. Sunil Jaybhane[5]

[1,2,5] *Institute of Pharmacy,Badnapur*

[3,4] *M. pharma Pharmacology (PhD), Institute of Pharmacy,Badnapur*

Abstract—**Drugs acting on the central nervous system (CNS) are widely used for the treatment of neurological and psychiatric disorders such as anxiety, depression, epilepsy, schizophrenia, pain, and Parkinson's disease. These drugs exert their effects by modifying neurotransmitter activity in the brain and spinal cord. Major neurotransmitters involved include gamma-aminobutyric acid (GABA), dopamine, serotonin, norepinephrine, glutamate, and acetylcholine. This review article discusses the classification, mechanism of action, therapeutic uses, adverse effects, and recent advances in CNS pharmacology. Understanding CNS drugs is essential for their rational and safe use in clinical practice.**

Index Terms—**Central nervous system, CNS pharmacology, Neurotransmitters, Psychotropic drugs.**

I. INTRODUCTION

The central nervous system (CNS) consists of the brain and spinal cord and plays a vital role in controlling sensory perception, motor activity, cognition, emotions, and behavior [15,17]. Disorders of the CNS are among the most common health problems worldwide and significantly affect the quality of life of patients [13]. Pharmacological agents acting on the CNS are used to treat a wide range of neurological and psychiatric conditions including epilepsy, depression, schizophrenia, pain, and Parkinson's disease [3,30]. These drugs primarily act by enhancing or inhibiting neurotransmitter signaling at synapses within the brain and spinal cord [33]. CNS pharmacology is considered a major branch of pharmacology due to the complexity of brain functions and the challenges associated with drug delivery across the blood–brain barrier [26].

II. NEUROTRANSMITTERS INVOLVED IN CNS FUNCTION

Neurotransmitters are chemical messengers responsible for communication between neurons in the CNS. The major neurotransmitters involved in CNS drug action include gamma-aminobutyric acid (GABA), glutamate, dopamine, serotonin, norepinephrine, and acetylcholine [15,33].

GABA is the primary inhibitory neurotransmitter in the CNS and plays an important role in anxiety, epilepsy, and sleep regulation [25]. Glutamate is the major excitatory neurotransmitter and is involved in learning and memory processes [15]. Dopamine regulates movement, motivation, reward, and psychotic behavior and is implicated in schizophrenia and Parkinson's disease [12,14]. Serotonin (5-HT) is involved in mood regulation, sleep, appetite, and emotional behavior [6,34]. Norepinephrine plays a key role in alertness, attention, and stress responses, while acetylcholine is important for memory, learning, and neuromuscular transmission [15].

Most CNS drugs act by altering the synthesis, release, receptor binding, or metabolism of these neurotransmitters [33].

III. CLASSIFICATION OF DRUGS ACTING ON CNS

Drugs acting on the CNS can be broadly classified into the following categories [17,30,37]
Sedative and hypnotic drugs
Antiepileptic drugs
Antipsychotic drugs
Antidepressant drugs
Analgesics (opioid and non-opioid)
Drugs used in Parkinson's disease
CNS stimulants

IV. MAJOR CLASSES OF CNS DRUGS

A. Sedative and Hypnotic Drugs

Sedative-hypnotic drugs are commonly used to reduce anxiety and induce sleep. Benzodiazepines and barbiturates are the most widely used agents in this category [1,9].

Mechanism of action: These drugs enhance GABA-mediated inhibitory neurotransmission in the CNS by increasing chloride ion conductance through GABAA_AA receptors [25].

Therapeutic uses: anxiety disorders, insomnia, and pre-anesthetic medication [11].

Adverse effects: Sedation, tolerance, dependence, and withdrawal symptoms on long-term use [1].

B. Antiepileptic Drugs

Antiepileptic drugs are used to prevent and control seizures by reducing abnormal neuronal firing [2,20].

Examples: Phenytoin, carbamazepine, valproate

Mechanism of action: These drugs act through sodium channel blockade, calcium channel inhibition, or enhancement of GABAergic transmission [29,31].

Adverse effects: Drowsiness, ataxia, hepatotoxicity, and drug–drug interactions [28].

C. Antipsychotic Drugs

Antipsychotic drugs are primarily used in the treatment of schizophrenia and other psychotic disorders [16,19].

Examples: Haloperidol, risperidone, olanzapine

Mechanism of action: Most antipsychotics act by antagonizing dopamine D_2 receptors in the mesolimbic pathway [12,21].

Adverse effects: Extrapyramidal symptoms, metabolic syndrome, and endocrine disturbances [21,22].

D. Antidepressant Drugs

Antidepressants are widely used for the management of depression and anxiety disorders [6,10].

Examples: Selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs)

Mechanism of action: These drugs increase synaptic levels of serotonin and/or norepinephrine by inhibiting their reuptake or metabolism [34,39].

Adverse effects: Dry mouth, sedation, weight gain, and sexual dysfunction [23]

E. Analgesics Acting on CNS

Opioid analgesics are effective in the management of moderate to severe pain [8].

Examples: Morphine, fentanyl

Mechanism of action: Opioids produce analgesia by activating opioid receptors in the CNS and inhibiting pain transmission pathways [27,36].

Adverse effects: Respiratory depression, tolerance, dependence, and risk of abuse [38].

V. ADVERSE EFFECTS AND SAFETY CONCERNS

Most CNS drugs are capable of crossing the blood–brain barrier, which increases their potential for central adverse effects such as sedation, cognitive impairment, tolerance, dependence, and drug–drug interactions [26,32]. Long-term therapy with CNS drugs requires careful monitoring to ensure patient safety and therapeutic effectiveness [32].

VI. RECENT ADVANCES IN CNS PHARMACOLOGY

Recent advances in CNS pharmacology include the development of selective receptor modulators, newer antidepressants and antipsychotics with improved safety profiles, pharmacogenomic approaches, and innovative drug delivery systems for targeted brain therapy [4,7,13,18].

VII. CONCLUSION

Drugs acting on the central nervous system play a crucial role in the management of neurological and psychiatric disorders. A clear understanding of their classification, mechanisms of action, therapeutic uses, and adverse effects is essential for rational and safe drug therapy [3,17]. Ongoing research continues to focus on developing safer, more effective CNS drugs with improved patient outcomes [4,13].

VIII. ACKNOWLEDGMENT

REFERENES

[1] Ashton, H. (2005). The diagnosis and management of benzodiazepine dependence. British Journal of Psychiatry, 186(3), 254–262. https://doi.org/10.1192/bjp.186.3.254

[2] Brodie, M. J. (2009). Antiepileptic drug therapy the story so far. The Lancet, 373(9678), 1086–1097. https://doi.org/10.1016/S0140-6736(09)60741-7

[3] Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2023). Goodman & Gilman's the pharmacological basis of therapeutics (14th ed.). McGraw-Hill Education.

[4] Conn, P. J., Roth, B. L., & Christopoulos, A. (2014). CNS drug discovery: Challenges and opportunities. Nature Reviews Drug Discovery, 13(9), 692–708. https://doi.org/10.1038/nrd4339

[5] Dauer, W., & Przedborski, S. (2003). Parkinson's disease: Mechanisms and models. Neuron, 39(6), 889–909. https://doi.org/10.1016/S0896-6273(03)00568-3

[6] Delgado, P. L. (2000). Depression: The case for a monoamine deficiency. Journal of Clinical Psychiatry, 61(Suppl 6), 7–11.

[7] DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2013). Innovation in the pharmaceutical industry: CNS drug development. Clinical Pharmacology & Therapeutics, 94(3), 329–336. https://doi.org/10.1038/clpt.2013.125

[8] Fields, H. L. (2004). State-dependent opioid control of pain. Annual Review of Neuroscience, 27, 199–225. https://doi.org/10.1146/annurev.neuro.27.070203.144219

[9] Griffin, C. E., Kaye, A. M., Bueno, F. R., & Kaye, A. D. (2013). Benzodiazepine pharmacology and CNS-mediated effects. Ochsner Journal, 13(2), 214–223.

[10] Hirschfeld, R. M. A. (2000). History and evolution of antidepressants. Journal of Clinical Psychiatry, 61(Suppl 8), 4–10.

[11] Holbrook, A. M., Crowther, R., Lotter, A., Cheng, C., & King, D. (2000). Meta-analysis of benzodiazepine use in insomnia. Canadian Medical Association Journal, 162(2), 225–233.

[12] Howes, O. D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: Version III. Schizophrenia Bulletin, 35(3), 549–562. https://doi.org/10.1093/schbul/sbp006

[13] Insel, T. R. (2012). Next-generation treatments for mental disorders. Nature, 483(7389), 278–279. https://doi.org/10.1038/483278a

[14] Jankovic, J. (2008). Parkinson's disease: Clinical features and diagnosis. The Lancet Neurology, 7(3), 240–250. https://doi.org/10.1016/S1474-4422(08)70038-0

[15] Kandel, E. R., Koester, J. D., Mack, S. H., & Siegelbaum, S. A. (2021). Principles of neural science (6th ed.). McGraw-Hill Education.

[16] Kane, J. M., & Correll, C. U. (2010). Past and present progress in antipsychotic drug treatment. Journal of Clinical Psychiatry, 71(9), 1115–1124. https://doi.org/10.4088/JCP.10r06264yel

[17] Katzung, B. G., & Trevor, A. J. (2021). Basic and clinical pharmacology (15th ed.). McGraw-Hill Education.

[18] Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery, 3(8), 711–715. https://doi.org/10.1038/nrd1470

[19] Lieberman, J. A. (1998). Pathophysiology and treatment of schizophrenia. American Journal of Psychiatry, 155(12), 1648–1659. https://doi.org/10.1176/ajp.155.12.1648

[20] Löscher, W. (1996). Basic pharmacology of antiepileptic drugs. Epilepsia, 37(1), 2–13. https://doi.org/10.1111/j.1528-1157.1996.tb00524.x

[21] Meltzer, H. Y. (2013). Update on typical and atypical antipsychotic drugs. Schizophrenia Bulletin, 39(1), 5–14. https://doi.org/10.1093/schbul/sbs161

[22] Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005). Treatments for schizophrenia. Molecular Psychiatry, 10(1), 79–104. https://doi.org/10.1038/sj.mp.4001551

[23] Nemeroff, C. B. (2007). Use of antidepressants in CNS disorders. Journal of Clinical Psychiatry, 68(Suppl 2), 17–25.

[24] Olanow, C. W., Obeso, J. A., & Stocchi, F. (2009). Continuous dopamine-receptor treatment of Parkinson's disease. Movement Disorders, 24(8), 1140–1148. https://doi.org/10.1002/mds.22559

[25] Olsen, R. W., & Sieghart, W. (2009). GABA A receptors: Subtypes provide diversity of function. Pharmacological Reviews, 61(2), 129–152. https://doi.org/10.1124/pr.109.001255

[26] Pardridge, W. M. (2012). Drug transport across the blood–brain barrier. Journal of Cerebral Blood Flow & Metabolism, 32(11), 1959–1972. https://doi.org/10.1038/jcbfm.2012.126

[27] Pasternak, G. W. (2010). Molecular biology of opioid analgesia. Clinical Journal of Pain, 26(Suppl 10), S3–S9. https://doi.org/10.1097/AJP.0b013e3181c49e21

[28] Patsalos, P. N. (2013). Drug interactions with antiepileptic drugs. CNS Drugs, 27(8), 703–726. https://doi.org/10.1007/s40263-013-0078-9

[29] Perucca, E. (2005). Pharmacological principles in epilepsy treatment. Epilepsia, 46(Suppl 4), 31–37. https://doi.org/10.1111/j.1528-1167.2005.463009.x

[30] Rang, H. P., Ritter, J. M., Flower, R. J., & Henderson, G. (2020). Rang & Dale's pharmacology (9th ed.). Elsevier.

[31] Rogawski, M. A., & Löscher, W. (2004). The neurobiology of antiepileptic drugs. Nature Reviews Neuroscience, 5(7), 553–564. https://doi.org/10.1038/nrn1430

[32] Schachter, S. C. (2016). CNS adverse drug reactions. New England Journal of Medicine, 374(16), 1586–1587. https://doi.org/10.1056/NEJMc1601609

[33] Snyder, S. H. (2018). Neurotransmitters, receptors, and CNS drug action. American Journal of Psychiatry, 175(3), 189–195. https://doi.org/10.1176/appi.ajp.2017.17090948

[34] Stahl, S. M. (2014). Mechanism of action of serotonin selective reuptake inhibitors. Journal of Clinical Psychiatry, 75(1), e01.

[35] Stahl, S. M. (2021). Stahl's essential psychopharmacology (5th ed.). Cambridge University Press.

[36] Trescot, A. M., Datta, S., Lee, M., & Hansen, H. (2008). Opioid pharmacology. Pain Physician, 11(2), S133–S153.

[37] Tripathi, K. D. (2023). Essentials of medical pharmacology (9th ed.). Jaypee Brothers Medical Publishers.

[38] Volkow, N. D., & McLellan, A. T. (2016). Opioid abuse in chronic pain. New England Journal of Medicine, 374(13), 1253–1263.

[39] Wong, D. T., Perry, K. W., & Bymaster, F. P. (2005). The discovery of SSRIs. Journal of Clinical Psychiatry, 66(4), 7–16.